Sutro Biopharma Balance Sheet Health
Financial Health criteria checks 6/6
Sutro Biopharma has a total shareholder equity of $149.6M and total debt of $4.1M, which brings its debt-to-equity ratio to 2.7%. Its total assets and total liabilities are $470.7M and $321.1M respectively.
Key information
2.7%
Debt to equity ratio
US$4.06m
Debt
| Interest coverage ratio | n/a |
| Cash | US$375.62m |
| Equity | US$149.65m |
| Total liabilities | US$321.09m |
| Total assets | US$470.74m |
Recent financial health updates
Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?
Aug 24
Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?
Feb 10Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?
May 02Is Sutro Biopharma (NASDAQ:STRO) A Risky Investment?
Dec 26Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?
May 07Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?
Jan 06
Recent updates
Bearish: Analysts Just Cut Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue and EPS estimates
Apr 02The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet
Mar 28Sutro Biopharma, Inc.'s (NASDAQ:STRO) Price Is Right But Growth Is Lacking After Shares Rocket 43%
Dec 19Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?
Aug 24Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?
Feb 10An Intrinsic Calculation For Sutro Biopharma, Inc. (NASDAQ:STRO) Suggests It's 47% Undervalued
Jan 12Sutro Biopharma: Partnership Progress Warrants Exposure
Aug 16New Forecasts: Here's What Analysts Think The Future Holds For Sutro Biopharma, Inc. (NASDAQ:STRO)
Aug 11Sutro Biopharma GAAP EPS of -$0.55, revenue of $28.1M
Aug 08Sutro to get $10M payment from Merck after first patient dosed in collaboration trial
Jul 26Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?
May 02Sutro; A Biotech To Watch With A Catalyst Rapidly Approaching
Dec 27Is Sutro Biopharma (NASDAQ:STRO) A Risky Investment?
Dec 26Sutro Biopharma initiated buy at H.C. Wainwright citing ADC candidates
Jun 18Industry Analysts Just Made A Sizeable Upgrade To Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue Forecasts
May 09Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?
May 07Sutro Biopharma EPS misses by $0.04, beats on revenue
May 07Sutro: Leading Cell Free Protein Synthesis Company With Promising Early Data
Jan 06Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?
Jan 06Financial Position Analysis
Short Term Liabilities: STRO's short term assets ($421.5M) exceed its short term liabilities ($93.7M).
Long Term Liabilities: STRO's short term assets ($421.5M) exceed its long term liabilities ($227.3M).
Debt to Equity History and Analysis
Debt Level: STRO has more cash than its total debt.
Reducing Debt: STRO's debt to equity ratio has reduced from 11.2% to 2.7% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: STRO has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: STRO has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 20.6% each year.